After seeing so many biotech share prices jump or plummet based on drug trials well before the drug is even approved, it is refreshing to discuss a company like Regeneron (NASDAQ:REGN). Regeneron's Eylea is experiencing incredible growth worldwide as a treatment for wet age-related macular degeneration, and the company is enjoying soaring profitability as a result. The stock is far from cheap, priced at 35 times forward earnings estimates, but Eylea has just gotten final approval from the European Commission for its macular degeneration indication in Europe, which means yet another market to add to the drug's dizzying growth story and more upward expansion from here.
